Literature DB >> 14703755

Pancreatic cancer since Halsted: how far have we come and where are we going?

Rebekah R White1, Ashish S Shah, Douglas S Tyler.   

Abstract

Entities:  

Mesh：

Year:  2003        PMID： 14703755     DOI： 10.1097/01.sla.0000097793.68830.5e

Source DB:  PubMed          Journal:  Ann Surg        ISSN： 0003-4932            Impact factor:   12.969


× No keyword cloud information.
  3 in total

1.  Significant growth inhibition of orthotopic pancreatic ductal adenocarcinoma by CpG oligonucleotides in immunodeficient mice.

Authors:  J Tepel; O Dagvadorj; M Kapischke; B Sipos; A Leins; B Kremer; H Kalthoff
Journal:  Int J Colorectal Dis       Date:  2005-08-16       Impact factor: 2.571

2.  No mortality among 100 consecutive pancreaticoduodenectomies in a middle-volume center.

Authors:  Yasuyuki Suzuki; Yasuhiro Fujino; Tetsuo Ajiki; Takashi Ueda; Tetsuya Sakai; Yasuki Tanioka; Yoshikazu Kuroda
Journal:  World J Surg       Date:  2005-11       Impact factor: 3.352

3.  Chemoradiotherapy with twice-weekly administration of low-dose gemcitabine for locally advanced pancreatic cancer.

Authors:  Hisato Igarashi; Tetsuhide Ito; Ken Kawabe; Terumasa Hisano; Yoshiyuki Arita; Toyoma Kaku; Ryoichi Takayanagi
Journal:  World J Gastroenterol       Date:  2008-09-14       Impact factor: 5.742
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.